• Samsung Biologics’ largest shareholder group’s stake rose to 74.3% from 74.29% in a Nov. 2, 2026, disclosure.
• Net purchases by Samsung Life Insurance’s special account increased the group’s holdings by 2,291 common shares to 34,393,937.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Samsung Biologics Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261102800547), on November 02, 2026, and is solely responsible for the information contained therein.